

Natural decline of testosterone in the middle aged men and hypogonadism have been reported to associate visceral obesity <sup>(26)</sup>. Few prospective studies have demonstrated a protective link between endogenous testosterone and CV events <sup>(27)</sup>. Earlier cohort studies have documented the association of high serum TG with the risk and mortality from ischemic heart disease and stroke <sup>(10,28,29)</sup>.

Increased levels of postprandial TG indicate the presence of increased levels of remnants from chylomicrons and VLDL <sup>(28)</sup>. These cholesterol-containing, triglyceride-rich lipoproteins penetrate the arterial endothelium, and may get trapped within the subendothelial space potentially leading to the development of atherosclerosis <sup>(30,31)</sup>. The majority of cross-sectional studies have found a positive correlation of endogenous testosterone with HDL and a negative correlation with total cholesterol, LDLc and triglycerides. Thus normal men with low testosterone appear to have adverse lipid profiles, and hypogonadal men have a potentially atherogenic dyslipidaemia prior to treatment <sup>(32,33)</sup>. These findings, together with previous reports on the importance of post prandial serum lipids in the prediction of atherosclerosis risk and consequent CVD <sup>(34,35)</sup>, may lead to the speculation that serum testosterone and postprandial TG levels (or either of them) are better predictors than fasting serum lipids for assessment of the CVD risk in normal men or those with classical dyslipidemia. This would, also, necessitate an early testing and early start of preventive measures.

## References

1. Antonio M, Gotto Jr. Cholesterol, Inflammation and Atherosclerotic Cardiovascular Disease: Is It All LDL? *Trans Am Clin Climatol Assoc.* 2011; 122: 256-89.
2. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries. *Lancet.* 2004; 364(9438): 937-52.
3. Fuster V, Kelly BB, Vedanthan R. Promoting global cardiovascular health: moving forward. *Circulation* 2011; 123: 1671-78.
4. WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of Diabetes mellitus. Geneva: World Health Organisation, 1999.
5. Bowman TS, Sesso HD, Ma J, et al. Cholesterol and the risk of ischemic stroke. *Stroke.* 2003; 34: 2930-34.
6. Shahar E, Chambless LE, Rosamond WD, et al. Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. *Stroke.* 2003; 34: 623-6.
7. Patel A, Barzi F, Jamrozik K, et al. Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. *Circulation.* 2004; 110: 2678-86.
8. Moreton JR. Chylomicronemia, fat tolerance and atherosclerosis. *J Lab Clin Med.* 1950; 35: 373-84.
9. Zilversmit DB. Atherogenesis: a post-prandial phenomenon. *Circulation* 1979; 60:473-85.
10. Freiberg JJ, Hansen AT, Jensen JS, et al. Non fasting Triglycerides and Risk of Ischemic Stroke in the General Population. *JAMA.* 2008; 300: 2142-52.
11. Yeap BB. Testosterone and ill-health in aging men. *Endocrinol Metab.* 2009; 5: 113-21.
12. Yeap BB. Are declining testosterone levels a major risk factor for ill-health in aging men? *Int J Impot Res.* 2009; 21: 24-36.
13. Eckardstein A, Wu FC. Testosterone and atherosclerosis. *Growth Horm IGF Res.* 2003; 13: S72-S84.
14. Khaw KT, Dowsett M, Folkard E, et al. Endogenous testosterone and mortality due to all-causes, cardiovascular disease and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. *Circulation.* 2007; 116: 2694-701.
15. Hayward CS, Webb CM, Collins P. Effect of sex hormones on cardiac mass. *Lancet.* 2001; 357: 1354-56.
16. Rosano GM, Leonardo F, Pagnotta P, et al. Acute anti-ischemic effect of testosterone in men with coronary artery disease. *Circulation.* 1999; 99: 1666-70.
17. Jankowska EA, Biel B, Majda J, et al. Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. *Circulation.* 2006; 114: 1829-37.
18. Jackson G. Testosterone deficiency syndrome (TDS) and the heart. *Eur Heart J.* 2010; 31: 1436-7.
19. Danzer H, Braunstein GD, Rasor J, et al. Maternal serum chorionic gonadotropic concentration and fetal sex predictions. *Fertil Steril.* 1980; 34: 336-40.
20. Batzer F. Hormonal Evaluation of Early Pregnancy. *Fertil Steril.* 1980; 34: 1-12.
21. Odell WD, Parlow AF, Cargille CM. Radioimmunoassay for human follicle-stimulating hormone: physiological studies. *J Clin Invest.* 1968; 47: 2551-62.
22. Moltz L, Schwartz U, Sorensen R, et al. Ovarian and adrenal vein steroids in patients with non-neoplastic hyperandrogenism: selective catheterization findings. *Fertil Steril.* 1984; 42: 69-75.